Inspire-MD

News & Events

23.5.13

InspireMD’s MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group

16.5.13

InspireMD to Announce Six-Month Results from the MGuard™ Embolic Protection Stent (EPS) MASTER Trial at EuroPCR

16.5.13

InspireMD Announces Reimbursement Coverage for MGuard™ Coronary Embolic Protection Stent (EPS) from Brazil’s Largest Private Insurer

8.5.13

InspireMD Reports Financial Results For Period Ended March 31, 2013

23.4.13

InspireMD Receives Approval from US Food and Drug Administration to Begin US Regulatory Trial

WELCOME TO InspireMD

InspireMD is a medical device company focusing on the development and commercialization of its proprietary stent platform technology – The MGuard net protective stent. MGuard is designed for high risk coronary patients – A market that consists of over 2 million patients per year worldwide.

*The MGuard is not available in the USA and Japan

For Doctors

This section is intended for doctors only

This section is intended to patients and their family members

This section is intended for shareholders and potential investors

News & Events

WELCOME TO InspireMD

For Doctors

For Patients

For Investors